Menlo Therapeutics Inc

61 articles about Menlo Therapeutics Inc

• Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting

  10/11/2019

  Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with psoriasis in an oral presentation at the 28th Congress of the European Academy of Dermatology and Venereology held in Madrid yesterday.

• 

  Clinical Catch-Up: September 23-27

  9/30/2019

  It was a moderately busy week for clinical trial news. Here’s a look.
• 

  A Look at the Year's Most and Least Successful Biotech IPOs

  1/3/2019

  Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
• 

  Comparing This Year's Big Biotech IPOs to Previous Years

  11/6/2018

  This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
• 

  Updated: Y-mAbs Therapeutics Looks at a $96 Million IPO

  9/21/2018

  New York-based Y-mAbs Therapeutics will look at securing $96 million through an initial public offering to support development of its antibody-based therapeutic treatments for cancer.
• 

  Biotech IPOs Are Booming … but for How Long?

  9/19/2018

  According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.

• Investigation On Behalf Of Menlo Therapeutics Shareholders For Recovery Of Investment Losses

  8/10/2018

  Thornton Law Firm LLP is investigating a potential lawsuit on behalf of purchasers of the securities of Menlo Therapeutics Inc. (NASDAQ: MNLO) pursuant or traceable to the registration statement and prospectus issued in connection with Menlo's January 2018 initial public offering ("IPO").

• SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Menlo Therapeutics Inc. (MNLO)

  8/1/2018

  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Menlo Therapeutics Inc.

• 

  Failed Clinical Trial: Menlo's Stock Tanks

  4/9/2018

  Menlo Therapeutics' stock dropped 55 percent in premarket trading after announcing its serlopitant failed to meet primary and secondary endpoints in a Phase II clinical trial.

• Menlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  1/29/2018

  Menlo’s common stock is listed on The NASDAQ Global Select Market under the ticker symbol “MNLO.”

• Bay Area's Menlo Therapeutics Prices IPO at $17 Per Share

  1/25/2018

  The offering is expected to close on January 29, 2018, subject to customary closing conditions.

• 

  Bay Area's Menlo Therapeutics Files for $98M IPO

  12/29/2017

  Menlo Therapeutics filed on Thursday with the SEC to raise up to $98M in an IPO.

• Menlo Therapeutics Begins Phase II Clinical Trial for Pruritus Associated with Psoriasis

  11/21/2017

  The PSORIXA study, MTI-109, is a multi-center, randomized, placebo-controlled study evaluating the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus associated with psoriasis.

• Menlo Therapeutics Initiates Enrollment in Phase II Clinical Trial with Serlopitant for Refractory Chronic Cough

  10/26/2017

  Menlo Therapeutics has initiated enrollment in a 170-subject Phase II trial evaluating serlopitant as a treatment for refractory chronic cough.

• Menlo Therapeutics Expands its Management Team

  10/17/2017

  Menlo Therapeutics is developing a neurokinin 1 (NK1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) associated with various underlying conditions, and for the treatment of refractory chronic cough.

• Menlo Therapeutics Release: Serlopitant Pruritus Reduction Results From Two Phase II Studies Presented At The 26th European Academy Of Dermatology And Venereology

  9/18/2017

• Menlo Therapeutics Raises $50 Million

  7/18/2017

• Menlo Therapeutics Announces Successful Pruritus Reduction Results From Phase 2 Serlopitant Trial (TCP-102) In 127 Subjects With Prurigo Nodularis

  3/8/2017

• Menlo Therapeutics Starts Enrollment In Two Phase 2 Studies For Pruritus Associated With Atopic Dermatitis And Pruritus Following Burn Injury

  1/9/2017

• Menlo Therapeutics Recruits Experienced Management Team And Board Leadership To Accelerate Development Of Serlopitant For Treatment Of Pruritus

  1/6/2017